Advertisements

CMBI Sees Potential in Innovative Medical Insurance, Favoring Key Biotech Firms

by Celia
What is Pre-Tax Health Insurance

CMBI has issued a research report noting a 14.1% year-to-date decline in the MSCI China Health Care Index, significantly trailing the MSCI China Index by 31.25%. This recent market volatility underscores the pharmaceutical sector’s notable resilience. With overseas interest rate cuts and improvements in China’s macroeconomic landscape, the pharmaceutical industry is poised to outperform the broader market.

Additionally, new health insurance negotiations are set to commence in China. While there are concerns regarding the financial balance of health insurance funds, the policy direction to support innovative drugs through these funds remains unchanged. CMBI particularly favors companies such as WuXi AppTec, BeiGene, Innovent Biologics, SKB Bio-B, Giant Biogene, 3SBIO, and Mindray Bio-Medical.

Advertisements

Related topics:

Advertisements
Advertisements

You may also like

blank

Bedgut is a comprehensive insurance portal. The main columns include commercial insurance, auto insurance, health insurance, home insurance, travel insurance, other insurance, insurance knowledge, insurance news, etc.

[Contact us: [email protected]]

© 2023 Copyright  bedgut.com